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Abstract 
Background: Over 50 Americans die each day from an acute opioid overdose. In 2015, over 
52,000 people died from a drug overdose. Given the gravity of the opioid epidemic within the 
United States, effective and expansive treatment methods are necessary to adequately address and 
reduce the impact of Opioid Use Disorders (OUD).  
Purpose: Opioid-agonist-based medication assisted treatment is the most effective 
pharmacological intervention to treat OUD. Unlike methadone, which is limited to specialized 
clinic settings, buprenorphine is a long-acting partially synthetic opioid medication approved for 
the treatment of Opioid Use Disorders since 2002. Despite the effectiveness of this 
pharmacological intervention and approval within office-based settings, like primary health 
centers, delivery of buprenorphine medication remains limited. The purpose of this literature 
review is to identify and synthesize the barriers to, beliefs surrounding, and benefits of 
incorporating office based opioid treatment (OBOT) in non-MAT specific settings. 
Methods: A literature search was conducted within PubMed to identify relevant peer-reviewed 
papers. Boolean search terminology was used, and the search was limited to papers published 
within the last five years. 
Results: Eight relevant articles were identified, which included qualitative and mixed-method 
studies. Literature revealed several barriers to buprenorphine treatment implementation including: 
 v 
concerns surrounding staff abilities, strict federal oversight, low perception of need for treatment, 
limited training within residency curricula, and stigma surrounding substance use. Beliefs 
discovered include the ideas that: patients with OUD are stressful and challenging, providers’ self-
perceptions that they are ill-equipped to meet patient needs, buprenorphine is “trading” addictions, 
and there is not enough time to treat individuals with OUD in clinical settings. Perceived benefits 
of implementation include a sense of satisfaction for being a part of the solution and the reward of 
watching a patient and their family heal. Given the gravity of the opioid epidemic within the United 
States, these findings have public health significance, as the research reviewed indicates major 
barrier to buprenorphine OBOT expansion and service provision. 
vi 
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The purpose of this paper is to identify the barriers to, beliefs surrounding, and benefits of 
buprenorphine office-based opioid treatment implementation within primary health care, family 
medicine, general practice, and other similar settings. The United States of America is 
experiencing a public health crisis with the current opioid epidemic, with over 50 individuals dying 
each day from acute overdose1. Untreated substance misuse costs the United States over $740 
billion per year2. Opioid-agonist-based medication assisted treatment is validated frontline care for 
the treatment of opioid use disorders (OUD)3. While methadone remains limited to specialized 
clinics due to federal regulations––primarily housed in urban areas––buprenorphine treatment has 
been approved for non-hospital and non-MAT-clinic specific settings since 20024. Office-based 
opioid treatment (OBOT) with buprenorphine has incredible public health significance as it is 
offers a unique opportunity to expand treatment service and availability, especially in rural areas5. 
Chapter 2 describes the background of the opioid epidemic, reviewing changes to the standards of 
pain management, and the increase of prescription opioid medication prescriptions written within 
the United States, the non-regulated marketing and promotion of such drugs, and the 
epidemiological and demographic data surrounding Opioid Use Disorders. Chapter 3 discusses the 
primary interventions of abstinence, cognitive behavioral therapy, and the opioid agonist 
medication approved for treatment. Chapter 4 discusses the literature search methodology used 
within this review and includes a PRISMA table and table of search results. Chapter 5 discusses 
the results of the Boolean terminology driven literature review, the major themes identified within 
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the peer-reviewed articles are presented. Chapter 6 summarizes and discusses the findings, 
recommendations and implications of this literature review. Limitations are also discussed. 
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2.0 Background 
2.1 The Problem of Pain 
Opioid-based narcotic medication and products have been used for centuries for their 
analgesic qualities and unique abilities to provide individuals with an experience of relaxation. 
These unique properties have also played a role in some individuals’ proclivities for using such 
substances for personal relief or pleasure, e.g., to get “high.” Before 1800, physicians considered 
pain a natural part of the human experience and aging process. During this time there was no 
regulation on opioid-based products, and they were regularly marketed to the public for a variety 
of ailments. The situation changed in the early 1900s when doctors began limiting the use and 
prescription of medication, to the point of demeaning patients with uncontrolled pain6. The passing 
of the Narcotic Control Act of 1974, which was written to eliminate illicit heroin use and 
prescription morphine dependence, reinforced the cultural beliefs inherent within the medical 
community at that time, and held opioid medication as a last-resort option for effective pain 
management6.  
After this legislation was passed, medical doctors were even more hesitant to use or 
prescribe opioid-based medications fearing their addictive qualities and the potential legal 
consequences. However, in 1973, just prior to the  passing  of the Narcotic Control Act, a 
manuscript was published that denounced the failure of medical professionals operating an 
inpatient unit to treat the pain of their patients7. This manuscript remained in the shadow of the 
1974 legislation change until the early 1980s when a few small retrospective studies were 
published that supported this manuscript and set the trajectory of pain management in the 21st 
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century. The first was a short five-sentence letter to the editor of the New England Journal of 
Medicine, which lacked scientific rigor yet stated: 
Recently, we examined our current files to determine the incidence of narcotic 
addiction in 39,946 hospitalized medical patients who were monitored 
consecutively. Although there were 11,882 patients who received at least one 
narcotic preparation, there were only four cases of reasonably well documented 
addiction in patients who had no history of addiction. The addiction was considered 
major in only one instance. The drugs implicated were meperidine in two patients, 
Percodan in one, and hydromorphone in one. We conclude that despite widespread 
use of narcotic drugs in hospitals, the development of addiction is rare in medical 
patients with no history of addiction8. 
The second piece, was a small retrospective study on 38 patients with chronic pain, of which the 
authors note only two patients developed a subsequent dependence on prescribed opioid 
medication6. These clinical opinions set the foundation for a sharp change in pain management 
and the strong stance of its under-treatment.  
This belief that the current state of practice was leading to in ineffective pain management, 
and the non-addictive qualities of opioids, slowly blossomed until the early 1990s. The Annals of 
Internal Medicine published an article in 1990 that bemoaned the “woeful neglect of the analgesic 
needs of the very sick and dying” and the American Pain Society launched a campaign calling 
“pain as the fifth vital sign” in 19956,9. Suddenly, with a new standard of care being established, 
major institutions and stakeholders came out against the perceived under-reliance on opioid 
analgesic medication, especially for acute pain6,10–12. An amendment to pain management within 
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the busy and burdened United States healthcare system seemed to happen overnight, rapidly 
swinging the pendulum from under-reliance on opioid analgesics to a deadly over-prescribing. 
These changes in perspective were adopted by the Joint Commission on the Accreditation 
of Healthcare Organizations, The Veterans Health Administration, and the wider medical 
community. In 1998, the Federation of State Medical Boards assured physicians they would 
experience no consequences for changing or increasing the frequency, amount and strength of their 
opioid prescribing.1 In 2004, the same Federation furthered their stance when they asked medical 
boards to hold clinicians accountable for under-treating pain, reprimanding doctors for any 
perceived under-prescribing of opioid medication pain treatment. Thus, clinical standards for pain 
management were changed, requiring physicians and health providers to manage physical 
discomfort and relieve symptoms of this “fifth vital sign” in a more drastic way. These changes in 
scope and approach dramatically increased the use and prescription of opioid analgesic 
medications, subsequent dependence, and ultimately, the opioid epidemic as we know it today.6,10–
12. 
2.2 Opioid Use Disorder 
Opioid Use Disorder (OUD) is a medical condition and chronic brain disease, defined in 
the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) as a 
“problematic pattern of opioid use leading to clinically significant impairment or distress”13. 
OUDs involve compulsive, repetitive drug seeking and use, despite the presence of negative 
consequences to an individual’s social, occupational, financial, or family functioning14,15. 
Individuals with opioid dependence experience an increasing loss of control over the amount of 
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their opiate intake, emotional dysregulation when drug access or use is prevented, and are at higher 
risk for contracting infectious diseases (e.g., HIV)14,16. The misuse of opioids produces changes 
within neurobiological brain structures and overall impairment of the reward pathways14,17–19. 
These changes, in combination with repetitive use, serve to increase tolerance, positively reinforce 
the negative habit, and create a long-term impact on overall health15,20.  
Per the DSM-5, diagnoses of OUD range from mild (2-3 symptoms), moderate (4-5 
symptoms), to severe (6 or more). Criteria for diagnosis must occur within a 12-month period and 
include: large quantities of opioid intake, increased desire for use and/or unsuccessful 
discontinuation of use, spending time in the acquiring, using or recovering from use, physical and 
psychological cravings, continued use despite consequences, loss of interest in social, recreational 
or employment activities, increased tolerance, and withdrawal13. 
Quality of Life (QOL) is poorer among individuals diagnosed with an OUD. Individuals 
with OUD score lower on physical and emotional well-being than the general population and 
individuals with other chronic illnesses (e.g., hypertension) and are impaired across many life 
domains, including activities of daily living, social and employment functioning, and overall 
health21. Additionally, the discriminating and disenfranchising effects of stigma have been shown 
to negatively impact an individual’s social functioning and overall health, compounding the 
already negative and socially ostracizing effects of OUDs22–29. 
OUD has a similar etiology and follows a pattern to other chronic health issues and should 
be treated as such18,19. Because of the chronic nature of OUDs, as well as the fact that it shares  
similarities of personal choice, impact and influence of the personal environment, and genetic 
liability components of other chronic illnesses like diabetes, asthma and hypertension,  individuals 
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with OUDs should be treated with the same care and respect from the medical wider community 
as those with these other diseases30,31. 
2.3 Epidemiology and Demographics 
Substance misuse costs our country over $740 billion per year in lost work, healthcare 
costs, and criminal justice expenses, and prescription opioid misuse account for over 10% ($78.5 
billion) of these costs2. Well over 50 Americans die each day from an acute opioid overdose, and 
over 50% of those deaths are related to a prescription medication1. Annual opioid overdose rates 
are higher than the peak death rates of firearms, automobile accidents, and HIV31. In 2014, over 
240 million opioid prescriptions were written within the United States, not including refills, and 
in 2015 over 52,000 people died from a drug overdose31–33. Over 38% of American citizens (more 
than 90 million individuals) use prescription opioids, 21-29% of individuals prescribed opioids for 
chronic pain misuse their prescription, more than 4% of the American population (more than 13 
million) uses prescription opioid medication for non-medical purposes, and 2.5 million individuals 
have developed an Opioid Use Disorder32,34–36. Of adults who misuse prescription opioid 
medication, nearly 60% report using without a prescription and over 40% report getting 
prescription medication from a friend or family member36. All of these factors play a role in the 
rising overdose deaths rates within the United States, which increased by 20% in 2016, totaling 
64,07033. Rates of emergency department visits involving prescription opioid medication went 
from 82.5 to 184.1 per 100,000 from 2004 to 201137. 
Racial disparities in opioid prescribing, especially for non-definitive conditions (e.g., back 
pain) may play a role in why whites experience the highest rates of opioid morbidity and 
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mortality38. Non-Hispanic whites are most likely to receive an initial opioid prescription, are at 
greater risk for non-medical use of such medication, and are most affected by heroin and 
prescription opioid related overdoses39. All ages, sexes, regions and urban locations of the United 
States experienced increases in opioid overdoses in 2016, particularly individuals age 35-54 years, 
urban locations (54%), and the Midwestern (70%), Western(40%), and Northeastern (21%) 
regions 40. Past-year heroin use among non-Hispanic white individuals has increased over 114%, 
and the highest rates of heroin use is seen amongst underinsured, low-income males, age 18-25, 
with over 61% of users reporting poly-substance use41,42. 
2.4 OxyContin 
The United States makes up 5% of the world’s population, uses 80% of the world’s opioid 
medication, and nearly 99% of the world’s hydrocodone. Over 4 million Americans have used a 
prescription opioid for non-medical purposes in the past year1,16. This dramatic over-prescription 
of medication did not happen overnight. On the coattails of the “fifth vital sign” and other 
resounding medical stakeholder support for increased opioid prescribing, Purdue Pharmaceuticals 
announced a new drug, OxyContin, in 1996. This “revolutionary” formulation was specially 
designed to provide a slow release of oxycodone, a semi-synthetic opioid medication for moderate 
to severe pain, over an 8-12-hour period6,43. Unlike most other oxycodone products and other 
opioid-based medications, this formulation was free of other pharmacological pain-relieving 
agents, such as acetaminophen or ibuprofen –– agents, traditionally found to be irritating (e.g., 
liver toxicity or stomach bleeding) to individuals using prescription opioids for non-medical 
purposes6,11,44. 
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Purdue quickly took advantage of the Federal Drug Administration’s (FDA) limited 
oversight of prescription marketing, producing aggressive and effective campaigns, utilizing a 
pharmaceutical salesforce of expertly trained personnel. Driven by OxyContin specific sales 
incentives, these pharmaceutical representatives went across the country to “educate” stakeholders 
on this powerful, effective, and “non-addictive” medication, obtaining incredible physician (and 
patient) buy-in. From 1996 to 2000, revenue from OxyContin grew from $48 million to nearly 
$1.1 billion; prescriptions for this new formulary rose from 670,000 to over 6 million6,11,44. By 
2010, OxyContin earned Purdue Pharmaceuticals $3.5 billion dollars and was the United States’ 
5th highest in brand name prescription medication sales12. 
Purdue continued its tactics in other ways, using the change towards a compassionate 
approach to pain management to its advantage45. Over 40 extravagant medical training retreats 
were held for nurses, doctors, pharmacists and other professionals at resort locations throughout 
their medical marketing efforts. In total, over 5,000 individuals attended these conferences, were 
recruited, and ultimately trained as ambassadors of the Purdue speakers’ bureau. Purdue claimed 
if you limit pharmacological intake to one time per day, you would reduce or eliminate misuse of 
the medication, also eliminating the risk of addiction. They backed up these claims with profiles 
detailing the favorable prescribing habits of individual physicians they claim matched national 
standards. Armed with this information and the call to successfully treat the fifth vital sign, 
physicians and other professionals returned home with new information and patient coupons for a 
free 7-30 day supply of OxyContin44. 
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2.5 Reformulation 
Purdue’s aggressive and falsified claims against the addictive qualities of its medication 
drew federal attention in 200712. The United States Drug Enforcement Administration pursued 
legal action against the company and Purdue pled guilty to falsifying marketing materials and 
downplaying the possibility of dependence with OxyContin. However, this court finding did 
nothing to curve OxyContin sales, which only continued to rise. It was not until 2013, when the 
Federal Drug Administration banned OxyContin from becoming a generic medication, that began 
to see a major acknowledgement and movement towards preventing the inherent misuse and 
diversion risks of this and other opioid based medications12. 
Days before Purdue was scheduled to lose its patent on OxyContin, the FDA blocked its 
advancement into a generic formulation. This block, designed to prevent further public health 
consequences from this drug, forced Purdue to reinvent their drug in a way that it was harder to 
use outside of its intended purposes (e.g., crush and intake through nasal passages). Changing the 
chemical makeup of this medication meant that individuals using it for medical and non-medical 
purposes were forced to adjust. It also meant that Purdue would maintain its stronghold on this 
medication, securing a new patent for this reformulation. Thus, driven by adverse physical 
consequences from this reformulation, individuals were forced to address their physical 
dependence to opioid-based medication through whatever means necessary6,11,12,46. 
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2.6 Prescriptions, Heroin and the American Population 
America’s evolution from the over prescription and misuse of opioid pain medication to 
illicit heroin use can be seen in within policy changes and pharmaceutical reformulation. 
OxyContin’s original formula is estimated to have the highest rate of non-medical use among all 
opioid analgesic medication12. Dosage of prescription medication is typically accepted as known, 
dependable and “safe” because it comes from a doctor and a pharmacy12. This belief helps prevent 
against internalized shame of being a “junkie” or an “addict,” regardless of whether the 
prescription came from their doctor or a dealer, removing the threshold of stigma surrounding 
heroin47. Data on the transition of from pills to heroin shows that an overwhelming number of 
individuals made this transition because of formulaic changes in medication or for financial 
reasons. Federally mandated changes to prescribing habits combined, with changes to a 
pharmaceutical makeup less likely to bring about desired effects, changed the route and style of 
opioid misuse39. When the pill supply chain was interrupted or low, the price too high, or the 
changed formula no longer effective for intended use, individuals could turn to heroin as a cheap 
and simple alternative. By that time their physical dependence was often so high that any shame 
and guilt surrounding a switch to heroin, a drug they used to look down on, was easily overlooked 
so the symptoms of withdrawal could be prevented.12,46–48. 
Changes in type of opioid use can be correlated to the formulaic switch in OxyContin’s 
less than desirable street value47,48. Since 2010, overdose deaths related to illicit non-prescription 
opioids has increase more than 200% and over 400,000 Americans have used heroin in the past 
month10,16,33. Heroin-related overdoses were stable from 1999-2006 but have been steadily 
increasing since 2007 49. Despite heroin being a drug that is completely banned by the united states 
federal government, it remains an inexpensive and easily accessed substance that is becoming 
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increasingly more dangerous with the introduction of Fentanyl, a fully-synthetic and highly potent 
opioid medication12,50. 
Fentanyl analogue use is steadily increasing within heroin supplies, used as a cheap filler 
to “cut” the product while also strengthening potency51. The effects of fully-synthetic opioid 
Fentanyl products––50 to 100 times more potent than Morphine and heroin––has dramatically 
increased mortality amongst the using population, as the levels of fentanyl within street products 
are unknown52,53. Prescribing rates of Fentanyl products have not increased within the United 
States, but Fentanyl-related emergency department visits increased by 104% between 2004 and 
2011, and Fentanyl related fatalities have risen by 79%52,54. The Drug Enforcement Agency 
reported a 259% increase in Fentanyl seizures from second half of 2013 to the first half of 201452. 
Perhaps even more alarming is the increasing discovery of Carfentanyl within heroin batches. This 
product,  designed for veterinary use on large animals, is 100 times more potent than traditional 
Fentanyl51–54. This rise in illicit Fentanyl and Carfentanyl use amongst illicit heroin batches and 
rising overdose rates demands a swift, inclusive and widespread medical approach to opioid 
dependent care. 
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3.0 Treatment and Other Interventions 
Given the gravity of the opioid epidemic, effective treatment and intervention methods are 
necessary to adequately address and reduce the impact of Opioid Use Disorders and prevent 
mortality. Within the literature, there are three primary treatment interventions within the clinical 
profession: Abstinence, Cognitive Behavioral Therapy (CBT) and opioid agonist medication 
assisted treatment or therapy (MAT) through methadone or buprenorphine. Each of them has been 
used independently, and more recently, clinicians and researchers are combining them to address 
OUDs from a multilayered perspective.  
3.1 Abstinence-Based Recovery 
Abstinence as an approach to opiate misuse, regularly pursued in conjunction with the 
spiritually based 12-Step model pioneered by Alcoholics Anonymous in 1935, has been shown to 
be the most common, longest used, yet most ineffective approach to opiate misuse55,56. People 
using abstinence-based interventions have demonstrated lower rates of treatment compliance, 
increased experiences of marginalization, higher rates of relapse, and greater psychological 
distress among individuals with an OUD as compared to those with any other substance use 
disorder57–59. 
Treatment professionals are working to combine this enduring intervention with other 
approaches such as Acceptance and Commitment Therapy (ACT) and Dialectical Behavioral 
Therapy (DBT). The addition of these validated, mindfulness-based treatment approaches to 
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mental and behavioral health concerns are used within inpatient and outpatient substance use 
disorder treatment settings to offer a fresh perspective to abstinence-based models. These 
modalities are used in conjunction with OUD treatment because they have exhibited strong 
potential to address the symptomology of co-occurring mental health disorders, all while 
complementing the core philosophy of the 12-Step model60,61. However, the addition of these 
models does not change the underlying approach of this model, nor does it assist individuals upon 
discharge, who are most at risk for using illicit substances upon community reentry.  
Due to its strict focus on abstinence from all mind-altering substances, including the proper 
administration of medication assisted treatment, it can be challenging to find 12-Step members 
and similarly grounded clinical practitioners to accept individuals on maintenance medication. 
Individuals on MAT are stigmatized and marginalized by the 12-Step community because they are 
not seen as sober, being in recovery, or having “clean” time57,58,62,63.  
3.2 Cognitive Behavioral Therapy 
Cognitive Behavioral Therapy is one of the most well-known and widely researched 
behavioral treatment intervention, effective for a variety of psychological and behavioral 
disorders64. It has been used effectively to treat depression, anxiety, schizophrenia, insomnia, 
smoking, eating disorders, and additional mood and health concerns65. CBT has been shown to 
assist individuals with OUDs to retain in treatment longer compared to other psychotherapeutic 
treatment interventions, helping to increase treatment outcomes, and positively impact co-
occurring mental health issues64–66. CBT has been shown to increase coping skills, self-image, 
self-esteem and self-efficacy64. It has been shown to be so effective that computer-based models 
 15 
are being tested to increase its availability. However, while effective within itself, especially with 
co-occurring disorders, it is most effective in the treatment of opiate misuse when combined with 
Medication Assisted Treatment67–69. Behavioral treatment of OUD without pharmacological 
intervention has shown that over 80% of individuals return to illicit drug use3. 
3.3 Opioid Agonist Medication Assisted Treatment  
Opioid agonist-based medication assisted treatment (MAT) with methadone, 
buprenorphine, or a buprenorphine and naloxone combination drug, is shown to be the most 
effective treatment intervention for opioid use disorders3. Opioid agonist MAT increases treatment 
retention, decreases the transmission of HIV and Hepatitis C, and reduces illicit substance use and 
mortality4,70. Long-term maintenance on these medications has the most promising treatment 
results, versus short-term use for detoxification3. Methadone is limited to practice within federally 
regulated clinics, primarily available within urban settings32,70,71. Buprenorphine is the only opioid 
agonist approved for office-based opioid treatment, allowing it to be used within primary health, 
family practice and other similar medical settings4. 
3.4 Methadone 
Methadone is a long-acting synthetic opioid, and full mu receptor filler, developed in the 
late 1930s3. Physician treatment of OUDs through the use of opioid–agonist-based medication was 
limited by the Harrison Narcotic Act of 1914. Around 25,000 physicians were indicted under this 
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act for using opioid medication to treat dependent patients, and approximately 2,500 of these 
physicians received a prison sentence71. For decades, despite the availability and known 
effectiveness of pharmacological treatment for OUDs, and two Supreme Court rulings that 
counteracted the Harrison Narcotic Act, physicians continued to limit their prescribing as a 
treatment for  opioid-dependence for fear of indictment71,72. Medical professionals took notice of 
methadone’s effectiveness in relieving the craving and withdrawal symptoms of patients with 
OUD in 1947, but no major changes to treatment standards were made until decades later3. 
In 1965, Dole and Nyswander produced an article equating opioid-dependence to a 
metabolic issue, similar to that of diabetes73. This laid the groundwork for specialized clinical 
settings to be established to treat OUD with the pharmacological advancements of methadone 
compared to traditional Morphine71. Unlike the short-acting morphine therapies used in the past 
that required multiple doses over the course of a day, methadone was shown to prevent craving 
and withdrawal symptoms over a 24-36 hour period71. This daily dose medication allowed a slow 
and necessary change in OUD treatment to begin. Subsequently, federally-regulated methadone 
treatment facilities established themselves in urban settings as the primary mechanism for MAT 
care within the United States. However, these clinics are greatly limited in their geographic scope, 
long waiting lists, limited acceptance of insurance, and daily clinical attendance required to receive 
the daily regulated dose74. Currently, an estimated 330,000 patients in the United States are 
enrolled in methadone maintenance programs, and these licensed clinics remain one of the most 
heavily regulated medical treatments within the federal government of the United States32,70,71. 
Guidelines for methadone recommend a minimum of 12 months maintenance for stabilization, 
with some clients electing for long-term methadone care32. 
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3.5 Buprenorphine 
Buprenorphine is a long-acting partially synthetic opioid medication, originally developed 
for pain management, that was approved in October 2002 by the U.S. Food and Drug 
Administration for opioid dependence within non-clinic settings4. This pharmacological 
intervention represents the first opioid-agonist medication available for office-based, primary care 
treatment since 1914. Buprenorphine is taken sublingually and retains agonist and antagonist 
qualities, having a strong affinity for, and partial filler of, the mu opioid receptor, while also acting 
as an agonist of the kappa opioid receptor. The medication works to stabilize the opioid receptors 
of an opioid-dependent individual72. 
While buprenorphine is less stigmatized within the medical and recovery communities than 
methadone, as it does not produce the same euphoria or sedation characteristics compared to full-
agonist opioids. Buprenorphine’s unique chemical makeup prevents withdrawal symptoms and 
cravings through its partial-filling of the receptors4. Buprenorphine has a plateau effect that 
prevents the drug from having any physical or psychological effect above a 16-32 milligram 
dosage and a strong half-life of up to 60 hours. Additionally, having a stronger affinity for the mu 
receptor compared to other opioids, buprenorphine reduces and overpowers the effects of other 
analgesic substances, such as heroin or OxyContin. These qualities allow for greater ease of dosage 
adjustment or withdrawal compared to methadone, and prevent respiratory depression and 
overdose due to its ceiling effect4,75. 
Shortly after FDA approval, another formulation of buprenorphine was released with a 4:1 
ratio with naloxone, an opioid antagonist, to prevent diversion and illicit use. Like buprenorphine, 
naloxone has a high affinity for, and binds strongly to the mu opioid receptor, working as an 
antagonist. However, as buprenorphine is administered sublingually, the bioavailability of 
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naloxone is limited in this fashion. If an individual attempts to alter the medication or administer 
it in a way other than as prescribed (e.g., intravenous), the naloxone would become activated, 
overpowering the buprenorphine and precipitating acute withdrawal symptoms for an opioid-
dependent individual4. 
Federal standards for buprenorphine prescribing to treat OUD were set by the Drug 
Addiction Treatment Act of 2000, allowing physicians to obtain a waiver through the Controlled 
Substances Act and treat up to thirty patients. In 2006, the Office of National Drug Control Policy 
Reauthorization Act increased the limit to 100 patients for practitioners who had prescribed 
buprenorphine at the previous limit for a minimum of one year. This limit was challenged, and in 
2016, addictions specialists were allowed to see up to 275 patients, and nurse practitioners and 
physicians assistants were also granted waivered prescribing of buprenorphine for OUDs76.   
Individuals receiving buprenorphine and counseling have significantly lower healthcare 
costs than individuals not receiving treatment, while buprenorphine-only treatment costs are 
similar to those of individuals participating in abstinence based counseling77. It is estimated that 
over 1.3 million citizens receive a prescription for buprenorphine/naloxone to treat an OUD, and 
more buprenorphine-based treatment products are being developed to sustain medication release 
and increase treatment retention32. However, despite these continued advancements in 
buprenorphine based pharmacological intervention, office-based opioid treatment remains limited 
beyond specialty clinics. These advancements in pharmacological research further highlight the 
need to further research on addressing the barriers preventing the expanded implementation of 
buprenorphine medication assisted treatment within primary healthcare and other similarly 
structured medical settings. 
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4.0 Methods 
Despite federal approval of buprenorphine prescribing for OUD in office-based settings 
since the early 2000s, a wealth of scientific literature supporting the effectiveness of this 
pharmacological intervention, buprenorphine office-based opioid treatment remains limited in 
availability within non-MAT-clinic settings (e.g., family medicine, primary health care, and 
general practice).75,78–81. Through critical literature review and synthesis, this thesis seeks to 
examine the current barriers against, beliefs about, and benefits of buprenorphine treatment for 
Opioid Use Disorders within office-based health care settings in the United States.  
4.1 Literature Search 
Boolean search criteria were created to identify academic studies exploring 
buprenorphine’s use in office-based settings. Search criteria was developed to incorporate 
common terminology for buprenorphine medication, including brand name drugs (e.g., 
Suboxone), common pharmacological combinations (e.g., naloxone) and familiar ways of 
describing such medical treatments (e.g., opioid replacement therapy). A PubMed search was 
conducted using the following terms: ((((buprenorphine [tiab] OR naloxone [tiab] OR suboxone 
[tiab] OR zubsolv[tiab] OR opioid replacement therapy [tiab] OR opioid substitution [tiab] OR 
opioid maintenance [tiab] OR medication assisted treatment [tiab]) AND (primary care [tiab] OR 
physicians[tiab] OR office based opioid treatment [tiab] OR primary health [tiab] OR office based 
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[tiab]) AND (drug dependence [tiab] OR opioid addiction [tiab] OR opioid abuse [tiab] OR opioid-
related [tiab] OR opioid dependence [tiab] OR opioid use disorder [tiab])))). 
4.2 Selection Criteria 
While buprenorphine waiver limits continue to increase, and buprenorphine office-based 
opioid treatment prescribing has been allowed for nearly two decades, the barriers to this treatment 
expansion remain relatively unknown. Parameters for this literature review were established to 
identify and describe the medical community’s view and treatment of OUDs with buprenorphine 
in office-based settings (e.g., primary health clinics). Additionally, studies evaluating patient 
perspectives were evaluated as a way of maintaining a well-rounded, holistic approach to the issue 
of barriers and expansion. Inclusion criteria for this review were articles: 
• Peer reviewed journals 
• Written in English 
• United States population focus 
• Published within the past five years 
• Office-Based Opioid Treatment (OBOT) settings 
• Buprenorphine focus 
• Evaluated physician and/or patient barriers 
• Evaluated physician and/or patient beliefs 
• Evaluated physician and/or patient perception of benefits  
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5.0 Results 
As demonstrated in Figure 1, the search resulted in 193 articles. Titles of these articles were 
reviewed and 106 were eliminated, as they did not meet inclusion criteria. Examples of excluded 
titles include “The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of 
Multilevel Barriers and Ways Forward to Promote Retention in Treatment” and Is Kratom the New 
'Legal High' on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance 
Abuse Potential”. “Acute pain management for patients receiving maintenance methadone or 
buprenorphine therapy”82,83. This left 87 articles eligible for abstract review. Upon abstract review, 
51 were excluded for not meeting the established inclusion criteria. An example of an article 
eliminated due to abstract criteria include “A Mixed Methods Study of HIV-related Services in 
Buprenorphine Treatment”84. Upon abstract review, 36 articles were reviewed and 28 were 
eliminated for not meeting inclusion criteria. An example of an eliminated article include “Acute 
Pain Management for Patients Receiving Maintenance Methadone or Buprenorphine Therapy”85. 
Research articles that met inclusion criteria for full review, description and discussion was 8. A 
summary of these articles and their literature characteristics is found in Table 1. Additionally, 
summaries of the three major themes identified within the results of this search are found in Table 
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Table 1 - A summary of the literature characteristics for the eight articles meeting the 
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Physician barriers to buprenorphine office-based opioid treatment were identified and 
discussed by seven of the eight studies found within this literature review. Studies show a lack of 
institutional or office support, concerns about time requirements for patient appointments and 
details required for federal documentation, issues with financial reimbursement, and 
misconceptions about medication assisted treatment as a viable and effective treatment option86–
88,90–93. Additionally, inflexibility and mandated or formalized treatment options were shown to be 
a barrier for treatment from the patient perspective in the eighth paper89. 
Table 1 Continued 
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5.1.1  Andraka-Christou et al. 
Semi-structured, in-depth, individual interviews were conducted with twenty licensed 
physicians in person or by phone. The purpose of these interviews was to identify barriers to 
OBOT, potential ways to minimize or address these barriers through policy change. Participating 
physicians were interviewed on their education, attitudes towards OBOT, perceived barriers and 
facilitators to OBOT, and potential policy changes to increase OBOT. Physicians interviewed were 
from Indiana (n= 16), Florida (n= 2), Wisconsin (n= 1), and Illinois ( n=1)86. Of those physicians, 
95% were white, 40% were female, and 90% practiced in an office-based setting. Twelve of the 
twenty participants had obtained a buprenorphine waiver and had experience prescribing it to treat 
OUD. The authors used a thematic analysis approach and Dedoose software to code and analyze 
the results. Their analysis identified numerous barriers to prescribing OUD treatment in office-
based settings, including:  
• Regulations for obtaining a waiver 
• Federal oversight and potential audit targeting 
• Patient limits and extra documentation requirements 
• Lack of training in substance use disorder treatment 
• Insurance or financial reimbursement barriers 
• Misunderstandings about pharmacological treatment for OUD 
• Fears of medication diversion or illegal activity occurring within the practice setting 
• Stigma about addiction and becoming a treatment provider for OUD86. 
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5.1.2  Andrilla et al.  
Qualitative telephone interviews were conducted with 43 rural physicians who had 
obtained a federal waiver to prescribe buprenorphine in office-based settings and were providing 
office-based opioid treatment. Participating physicians were found through the 2016 Rural Health 
Research Center (RHRC) survey. Investigators followed a semi-structured interview guide that 
was based on the physician’s responses to the RHRC survey. The purpose of this study was to 
evaluate the process and means by which participants overcame barriers to OBOT treatment. The 
mean age of the participants was 55.6 years, 25.6% were female, and only 9.3% of them were 
waivered to prescribe up to 100 buprenorphine patients. Regions of participant practice were 23% 
Northeast, 20.9% Midwest, and 27.9% West and South. Results showed that participants felt great 
barriers exist for physicians, creating major deterrents to becoming waivered and prescribing 
buprenorphine. Primary barriers identified by physicians were: 
• Amount of time required per visit 
•  Remuneration rates 
• Extra paperwork and federal regulations 
• Financial viability of OBOT 
• Becoming overwhelmed by the change to one’s practice 
• Medication misuse or diversion 
• Lack of support, referral resources, or mentoring options87. 
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5.1.3  DeFlavio et al. 
Anonymous qualitative and quantitative surveys were conducted with 108 family 
physicians practicing in Vermont (n= 45) or New Hampshire (n=63) to evaluate barriers to 
integrating buprenorphine therapy within office-based family physician practices. The 
questionnaire developed for this study followed the principals of rigorous survey design by 
reviewing literature, drafting a survey based upon their review, and piloting it to establish validity. 
A twenty-statement survey, utilizing a five-point Likert scale, was conducted on the domains of 
buprenorphine OBOT adoption, opinions of addiction, and opioid treatment options. Physicians 
perception of patient factors and logistical concerns were also assessed. There was an even 
representation of self-identified female (n=54) and male participants (n=54), and over 50% of 
practitioners had been out of school for more than 15 years. Of the sample, only 10% prescribed 
buprenorphine, though 80% reported regularly seeing patients physically dependent on opiates and 
73% report feeling a personal responsibility to treat addictions. A large majority of the physicians 
(94%) believed that treating individuals with OUD was difficult. Only 25% reported confidence 
in treating OUD, and 28% reported confidence in treating potential comorbidities. Logistical 
barriers such as untrained staff (88%), lack of time (80%), minimal office space (49%) and 
intensive OBOT regulations (37%). Reimbursement was another barrier, with nearly half of the 
physicians stating there should be a special rate for buprenorphine OBOT. The open-ended section 
of the survey, of which 75% of physicians participated, showed barriers for them and their staff in 
terms of things lacking: time for, interest in, and knowledge of OUD and OBOT. Of this qualitative 
section, time was the most noted barrier. A barrier of mistrust was also noted in the qualitative 
section, stating a general mistrust of patients with OUD, as well as buprenorphine OBOT. 
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Additionally, physicians saw patients with OUD as “difficult”, “stressful”, “challenging” and 
“high-maintenance.” 
5.1.4  Fox et al. 
Five focus groups were held with 33 adult patients with experience in receiving office-
based buprenorphine care from a Federally Qualified Health Center (FQHC) in Bronx, NY. The 
purpose of this study was to identify patients’ experiences with buprenorphine OBOT and their 
preferences in psychosocial supports and other factors. This clinic serves a primarily low-income 
population that is 57% Hispanic and 39% Black. Patient participants state that, overall, 
buprenorphine OBOT assisted them in achieving their treatment goals. They appreciated the 
flexibility, privacy and accountability available within buprenorphine OBOT. Participating 
patients in this study identified barriers to care within their provider/patient relationships. Patient 
barriers for this treatment include: 
• Physician inflexibility in decision making  
• Fear of being discharged from the treatment program for illicit drug use  
• Judgmental and stigmatizing interactions with providers 
• Forced participation in specific treatment (e.g., group counseling)  
• Treatment that was not individualized 
• Treatment that was not private or confidential 
• Not feeling safe to process and self-disclose 
• Non collaborative or cooperative care models89. 
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5.1.5  Huhn et al.  
Anonymous mixed-method surveys were conducted with 558 physicians, with or without 
a waiver, from rural (18.3%), suburban (40%) and urban (41.8) locations across the Northeast 
(24.7%), Midwest (19.5%), South (36.7%) and Western (18.8) parts of the United States. The 
purpose of this survey was to asses and evaluate perceived barriers to federal waiver and actual 
prescribing of buprenorphine for OUD. Results of this study showed that primary barriers to 
waiver and prescribing were time constraints (19.2%) and lack of knowledge about the waiver 
process (14%). Of the participants not waivered to prescribe buprenorphine, over 33% of them 
reported no willingness to prescribe it, and they indicated that no additional resources or would 
change their perceived willingness for OUD treatment. Of waivered prescribers, 56.2% (n= 272) 
were not prescribing to patient capacity, and of those respondents, 54.8% indicated they were 
unwilling to increase their current patient amount. The authors noted that physicians not 
prescribing to waiver capacity was associated with rejecting patients interested in buprenorphine 
treatment, perceived time constraints, lack of information about proper buprenorphine induction 
procedures, and the conviction that reimbursement rates for OUD treatment was inadequate. 
Regardless of waiver status, lack of knowledge and an unwillingness to change practice and 
prescribing habits showed to be a statistically significant barrier to buprenorphine treatment access. 
Barriers to buprenorphine OBOT identified in this article are: 
• Time constraints 
• Lack of knowledge about waiver process 
• Lack of willingness to prescribe 
• Lack of willingness to change their stance 
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• Not prescribing at capacity 
• Rejection of interested patients 
• Lack of information on buprenorphine induction 
• Concerns about remuneration rates90 
5.1.6  Hutchinson et al. 
Interviews on barriers to buprenorphine treatment were conducted with 78 primary care 
physicians who had recently completed a training program through the Washington State’s Rural 
Opioid Addiction Management Project. Participants in the study were 40% female with a mean 
age of 52.1, practicing in primarily urban counties (69%). Physicians were surveyed on 
demographic information, the features of their medical practice, and their perception of barriers to 
buprenorphine OBOT. Physicians who were not currently prescribing buprenorphine OBOT 
reported a lack of organizational support. The most frequently cited barrier was lack of mental 
health support (64%), time constraints (54%) and lack of support from a substance use disorder 
specialist (45%) and lack of confidence in their ability to treat patients with OUD (41%). Most 
interesting was 42% of physicians reporting opposition from a colleague within their practice, as 
well as a wider lack of agency or institutional support (36%). Only 28% reported remuneration as 
a barrier to buprenorphine OBOT. 
5.1.7  Tesema et al. 
The purpose of this study was to assess physician residency programs and their provision 
of OBOT training within their training. Relevant literature was reviewed, and interviews were 
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conducted with primary care and other office-based physicians to ensure proper study domains. 
Semestructured interviews were conducted on 10 physicians to gain feedback and assess face 
validity. The final 13-item survey was conducted with 476 program directors of accredited United 
States internal, family and psychiatric medicine residency programs. The survey was designed to 
assess curriculum standards surrounding OUD and OBOT, number of hours devoted to OBOT 
training, the frequency of residents treating OBOT within the respective programs, if programs 
encourage or require residents to obtain a buprenorphine waiver, and potential barriers to receiving 
or implementing such training. Additionally, beliefs surrounding OBOT, the association of the 
program directors’ beliefs to OBOT curriculum availability were evaluated. The directors 
surveyed oversaw residency programs that were primarily in urban settings (85.9%) within the 
Western (17.7%), Southern (30.3%), Midwest (25.4%) and Northeast (26.6%) regions. Over 75% 
of residential directors report that residents manage patients with OUD, but less than 25% of them 
report their residency programs having over 12 hours of dedicated training to OBOT. The most 
frequently reported barriers to the incorporation of OBOT curriculum within resident training 
programs include: 
• Perception of a limited resource of waivered preceptors (76.9%), 
• More important education priorities within the curriculum (64.1%) 
• Limited mental health supports (54%) 
• Negative beliefs about patients with OUD held by preceptors (over 20%) 
• Negative beliefs about patients with OUD held by residents (nearly 30%)92. 
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5.1.8  Tong, et al. 
Tong, et al. used a cross-sectional study design to analyze the data collected within the 
2016 National Family Medicine Graduate Survey, completed by physicians who completed 
residency in 2013. The purpose of this study was to evaluate whether their residency program 
effectively prepared physicians for buprenorphine OBOT and if buprenorphine waivered 
prescribing was part of their current practice. Additionally, the authors looked to establish 
associations between personal, residency program, and medical practice characteristics. Of the 
1,979 surveys evaluated within this study, 10% (n = 198) reported receiving adequate 
buprenorphine training within their program, and only 7% (n=138) reported offering 
buprenorphine treatment within their office-based medical practice. Of the physicians who 
prescribe buprenorphine OBOT, less than half (n=63) report feeling prepared by their residency 
program to do so. The survey further demonstrated that over two-thirds of individuals trained in 
prescribing buprenorphine for OUD are not doing so. The results of this study show that residency 
training is a significant barrier associated to the limited delivery of buprenorphine as an office-
based treatment option93.  
5.2 Beliefs 
Personal beliefs surrounding individuals with an opioid use disorder, opioid agonist-based 
medication assisted treatment, and one’s ability to effectively implement and provide care has a 
significant impact on availability of OBOT. Results from this literature review show that a general 
bias against individuals with an opioid use disorder is pervasive within the medical community. 
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Physicians responsible for the training and direction of medical residents may communicate their 
beliefs and prejudices against persons with OUD. Furthermore, personal beliefs may play a role in 
how OBOT is treated and discussed within educational curricula, reflected in individual or 
communal office-based practice settings. 
5.2.1  Andraka-Christou et al. 
Within this study, a general belief held by providers was that they felt personally ill 
equipped to treat OUD as an office-based practitioner, without models or mentors for how to 
engage patients in questions surrounding substance use. Participants attributed this to the lack of 
extensive or formalized training, with most of the programs only offering addiction medicine 
training as an elective. They further noted that rotations within such departments was also limited. 
Authors reported the second most common belief was that individuals with an opioid use disorder 
were “difficult.” Participants feared individuals might bring illegal activity within the practice, 
might use buprenorphine as “just another drug,” and the more stringent government oversight, not 
worth the extra time and steps required with patients, and additional documentation was not worth 
it. These beliefs encourage practitioners from attaining and utilizing a buprenorphine waiver, 
ignoring OUD symptomology within their patients. The belief that staff was limited in their ability 
or desire to engage with OUD clients, and that one might be labeled as the community “addiction 
treatment provider” and subsequently stigmatized for it was also noted86. 
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5.2.2  Andrilla et al. 
Authors of this study evaluated practitioners who had effectively implemented 
buprenorphine treatment within rural medical practices. Several facilitators of OBOT were noted. 
The Physicians’ surveyed within this study held positive beliefs surrounding OUD and medication 
assisted treatment, though it is noted that does not readily exists within the medical community. 
The physicians within this study note this poses a threat to providers becoming waivered and 
offering buprenorphine treatment, and that it is necessary and important to find and implement 
solutions to combat these barriers. In discussing their encouragement to other providers to 
prescribe buprenorphine, recognizing their part in contributing to the opioid epidemic through 
overprescribing, and their subsequent need to be part of the solution, one participant stated, “I tell 
them you must, you must. You did it, I did it, we all did it, we are all in this together, and now we 
need to help fix it.” Participants noted their belief that mentoring is important and readily available 
in a variety of formats (e.g., digital, phone and in-person). They also indicated that, in general, 
creating boundaries and accountability with patients is important for both parties, and prevents 
many of the fears surrounding office-based opioid treatment from occurring. They note that well-
established models for implementation exist, and that having honest conversations with colleagues, 
administrators and other staff members can dispel institutional fear. Additionally, such 
conversations will help humanize clients with OUD, creating an open, collaborative, and positive 
treatment environment everyone involved87. 
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5.2.3  DeFlavio et al. 
Within the open-ended response portion of this study, all respondents noted that working 
with individuals with OUD was challenging. Physicians believed that individuals with OUD were 
not trustworthy and had strong concerns about working with individuals who have histories of 
substance misuse. Respondents noted not wanting to “deal with addicts who lie,” while another 
spoke of their office not operating “as a police agency.” Physicians noted their own personal beliefs 
and biases as a deterrent from offering buprenorphine within their office-based practices as clients 
are “high-maintenance,” “stressful,” “challenging,” and “trading one addiction for another.” 
Additionally, physicians questioned buprenorphine as a long-term maintenance treatment. The 
belief that one was not capable of meeting the needs of OUD clients and successfully addressing 
potential comorbidities was common. However, the most commonly cited belief was that their 
staff was ill-equipped to work with individuals with OUD, and that nobody in the office had 
sufficient time to administer and regulate buprenorphine treatment. Interestingly, and slightly 
contradictory to the results, this study shows that despite the negative beliefs surrounding OBOT 
and patients with OUD, family practitioners believe that because they regularly see individuals 
who are opioid dependent patients, and they state they have a certain responsibility to treat it88. 
5.2.4  Fox, et al. 
Fox, et. Al. note that, overall, focus group patients believe that office-based buprenorphine 
treatment, complemented by collaborative, patient-centered care within flexible, accessible, 
confidential, non-judgmental environments, helped them to achieve their recovery goals. 
Participants believed that the relationship developed with their practitioner was instrumental in 
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their recovery, stressing the importance of having a safe place to share personal information 
without the fear of rejection or reprisal. Another participant, noting their belief in the importance 
of honesty within the client/provider relationship, stated, “I gotta be open with my doctor just like 
she’s gotta be open with me. We gotta be 50-50 on the same page, you know.” Participants further 
shared their beliefs that providers need to be comfortable discussing a wide range of topics, as well 
as the importance of shared decision making with treatment plans and buprenorphine dosing. “If 
you don’t have that personal communication with your doctor, it’s not gonna work no matter what 
they’re giving you.” Some participants noted their belief that counseling requirements within 
buprenorphine treatment should be self-selected, and that group therapy was not helpful for 
everyone. Additionally, inclusive, comprehensive, team-based care was important. As one 
participant said, “Everybody has to work together – the pharmacist, the therapist, the doctor – 
everybody has to work together trying to find me treatment, and alleviate the problem that you’re 
having.” 
5.2.5  Tesema et al.  
This study found that most residency directors surveyed (88.1%) believe that office based 
opioid treatment (OBOT) is an important option for OUD, that the current number of OBOT 
providers is insufficient for meeting community needs (75.3%), and that an increase in OBOT 
training within residency programs would increase the provision of such services within the 
community (73.7%). However, only 36.5% believe that OBOT should be a mandatory part of the 
curriculum. Interestingly, of the program directors who had favorable views of buprenorphine and 
OBOT, there were significant odds of those same directors encouraging or requiring residents to 
get a waiver or offering twelve or more hours of training in OBOT. One out of five respondents 
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reported they believe pessimistic views and attitudes towards individuals with OUD exists with 
clinic preceptors and resident doctors, and that these views hinder the adoption of OBOT 
curriculum and eventual office-based practice92. 
5.3 Benefits 
Treatment options within the United States remain limited, despite buprenorphine’s 
validated effectiveness and FDA approval for office-based settings since the early 2000’s. 
Research on barriers to implementation remain limited, and qualitative data on the personal 
benefits that patients and physicians receive from incorporating this treatment is even more 
restrained. Two studies included in this review focus on the qualitative experience of patients and 
providers, highlighting the personal benefits of receiving and providing buprenorphine treatment 
in office-based settings.  
5.3.1  Andrilla et al. 
Participants within this study noted the rewarding components of offering buprenorphine 
treatment within their office-based practices. One physician said, “It is the most satisfying, 
personally nourishing medical activity I’ve done in my practice lifetime,” and another stated, “This 
is by far the most rewarding area of medicine I have ever practiced in.” Beyond personal 
satisfaction for providing treatment, physicians shared the happiness and fulfillment they got to 
witness within the lives of their patients, their families, and the wider community they practice in. 
“No one gets excited because their blood pressure is under control, or their diabetes is better, but 
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the addiction patient that gets better, it just has ripple effects through the whole community. It 
keeps families together, moms and children and grandparents are much happier, so it’s much more 
rewarding in a lot of ways than routine family care.” Another physician shared that their biggest 
success stories are when families are able to come back together and heal as a result of 
buprenorphine treatment. “They’re the best stories of all I have to say. And they’re worth it.” 
Importantly, physicians shared the benefit of having a role in addressing the opioid epidemic – an 
epidemic they are often and easily blamed for. As one participant stated, “I am really proud to be 
part of the solution87.” 
5.3.2  Fox et al. 
Patients within this focus group-based study freely shared the benefits of receiving 
buprenorphine treatment for OUD in an office-based setting. Participants noted the comfort and 
acceptance they received within their care, and the psychosocial benefits of receiving it from their 
primary care provider. When discussing the benefits freely sharing the difficulties of with a non-
judgmental provider, one participant stated, “You put it out there, you get it off your chest, it just 
makes you a better person.” This kind of relationship fosters honesty and accountability in OUD 
treatment, another benefit shared by the participants. “I gotta be open with everything. I can’t hide, 
I can’t even sugarcoat it or… imma go out there and get high.” Another participant noted, “I could 
talk to her about anything that I’m going through. And she understands.” This benefit was 
something perceived and received within an office-based setting, and many found a benefit of 
receiving it in a collaborative care environment. “With my doctor, there’s another counselor there 
and he asks me how I’m doing in the week. Do I have any problems…He works side to side, when 
I go to see the doctor for my [buprenorphine], I’m still getting counseling. So it’s a little bit of 
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everything.” The greatest benefit within the lives of these participants attributed to caring, non-
judgmental physicians who used shared-decision making to create individualized treatment plans 
within a patient-centered model of care89.  
 40 
Table 2 - A summary of the findings surrounding barriers to, internalized beliefs about, 
and personal benefits of buprenorphine office-based opioid treatment implementation. 







• Federal Regulations 
for obtaining a waiver 
• Federal oversight and 
audit targeting 
• Patient limits 
• Extra documentation 
requirements 
• Lack of training in 
OUD treatment 





• Concerns about 
medication diversion 
• Concerns about 
illegal activity in the 
office 
• Stigma based 
perception about 
OUD 
• Concerns about being 





perception that they 
are ill-equipped to 
treat OUD 
• Individuals with 
OUD are “difficult” 
• Patients might 
conduct illegal 




just switching drugs 
• Federal oversight is 
too stringent 
• The extra time 
needed to treat 
patients is not 
beneficial 
• Staff is limited in 
their capabilities 
• Staff is limited in 
their desire to have 
clients with OUD 







• Time spent with 
patients 
• Remuneration rates 
• Extra paperwork 
• Federal regulations 
• Financial viability 
• Being overwhelmed 
• Medication diversion 
• Lack of support 







• Offering treatment 
allows them to have 
a role in addressing 
the opioid epidemic 
• Time requirements 
are not too intense 
• They must play a 
role in the solution 
• Benefit of offering 
treatment that is 
satisfying and 
rewarding 
• Benefit of offering 





• Benefit of being a 
part of the solution 
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• Lack of mentoring • Mentoring is 
important 
• Mentoring is 
available. 
• Boundaries and 
accountability with 
clients are important 
• Established models 
of care for 
implementation exist 
• Having honest and 
open conversations 
with staff is 
important 
• Collaborative 
models of care are 
important 








• “Difficulty” of 
patients with OUD 
• Concerns about 
remuneration 
• Lack of knowledge 
about OUD treatment 
• Lack of interest in 
OUD treatment 
• Lack of time for 
OUD treatment 
• Lack of confidence in 
buprenorphine 
treatment 
• Concerns about 
medication diversion 
• Concerns about staff 
capabilities 
• Individuals with 
OUD are not 
trustworthy 








• Clients are “trading” 
addictions 
• Buprenorphine is not 
effective long-term 
• Not capable in 
meeting the needs of 
clients with OUD 
• Cannot address any 
comorbidities 
• Staff is not equipped 
for implementation 
• There is not enough 















• Non-shared decision 
making 
• Forced participation 
in treatment elements 
• Fear of being 
discharged for illicit 
use 
• Judgement or 
stigmatization from 
providers 




• Practitioners were 
safe and non-
judgmental 
• Honesty is important 
from patient and 
provider 
• Collaboration and 
communication are 
important 
• Independence with 
one’s treatment is 
important 
• Team-based models 
of care work 
effective 
• Personal election of 
counseling supports 
• Benefit of being 
met by provider 
without judgement. 
• Benefit of 
receiving OUD 
and medical care 
together 
• Benefit of honesty 
and accountability 
• Benefit of having 
collaborative care 
• Benefit of shared 
decision making 
• Benefit of 
individualized care 




• Time constraints 
• Lack of knowledge 
about waiver process 
• Lack of willingness 
to prescribe 
• Lack of willingness 
to change their stance 
• Not prescribing at 
capacity 
• Rejection of 
interested patients 
• Lack of information 
on buprenorphine 
induction 









• Lack of knowledge 
about mental health 
resources 
• Lack of access to 
mental health 
resources 
• Time constraints 
• Lack of backup from 
an OUD specialist  
• Resistance from 
colleagues 
N/A N/A 
Table 2 Continued 
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• Lack of institutional 
support 
• Limited confidence in 
ability to treat OUD 
• Remuneration 
concerns 
• No perceived need 
for buprenorphine 
treatment 





• More important 
education priorities 
• Limited mental health 
supports and 
resources 
• Negative beliefs 
about OUD held by 
clinic preceptors 
• Negative beliefs 
about OUD held by 
residents 
• OBOT is an 
important option 
• Current number of 
providers is 
insufficient 
• Increasing OBOT 
training in residency 
would help increase 
number of waivered 
physicians 
• Pessimistic views of 
individuals with 
OUD hinders 






• Lack of residency 





Table 2 Continued 
 44 
Table 3 - Barriers to and personal beliefs about OBOT identified in two or more articles. 
# of Articles Barriers 
5 
 
• Remuneration Rates86–88,90,91  
• Concerns about time86–88,90,91 
 






• Concerns about buprenorphine diversion86–88 
• Lack of knowledge about psychosocial supports and resources87,91,92 
• Lack of training in OUD and OBOT86,90,93 










• Lack of training in OUD86,93 
• Federal oversight and regulations86,87 
• Extra documentation requirements86,87 
• Lack of interest in buprenorphine OBOT88,90 
• Concerns about the efficacy of Buprenorphine86,88 
• Lack of staff, colleague or institutional support87,91 
# of Articles Negative Beliefs 
2 • Individuals with OUD are “difficult” or “challenging”86,88 
• Staff is limited in desire and capability to implement OBOT86,88 
• Providers believe they are ill-equipped to provide OBOT86,88 
 
# of Articles Positive Beliefs 
2 • Buprenorphine OBOT is an important and necessary option87,92 
• Collaborative care models are good and important87,89 
• Honesty and accountability are important for patients and providers87,89 
 
 




6.1 Summary of Findings 
Buprenorphine treatment integration within office-based medical settings remains limited, 
despite over a decade of federal approval5,94. This literature review summarizes previous studies, 
showing that significant personal and institutional barriers still exist against the provision of this 
within this validated pharmacological intervention in office-based settings75,78–80. Primary barriers 
for physicians identified in this review include: limited training in office-based opioid treatment 
within physician residency curricula; concerns about remuneration for buprenorphine services; 
perception that MAT is not needed within one’s current patient population; limited knowledge of 
mental health services within the local community; no behavioral health services available within 
their particular practice; apprehensions about medication diversion; conflicting feelings 
surrounding agonist therapy (e.g., switching addictions);  stigma surrounding individuals with 
OUD and their illicit use of  substances (e.g., “difficult” patients); a staunch resistance to change, 
regardless of education or resources available; time constraints; reservations about staff 
capabilities; lack of institutional or collegial support. However, this literature review also shows 
that overcoming such barriers and beliefs is possible, and the results of such enterprises are 
rewarding for practitioners and their patients. 
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6.2 Discussion of Findings 
Opioid Use Disorder is a chronic medical condition of epic proportions within the United 
States. Persons with untreated OUD have poorer quality of life and physical well-being compared 
to the general population and individuals with other chronic illnesses22. Significant stigma 
surrounds these individuals, further complicating their health and social functioning, and 
increasing the alarming overdose death rates1,23. Tens of thousands of lives have been lost to OUD 
and billions of dollars are spent each year due to healthcare costs, lost work, and criminal justice 
expences2. 
Buprenorphine-based opioid agonist therapy is a viable and effective treatment option, 
approved for use within office-based medical settings; the first agonist therapy available within 
non-OUD specific treatment settings since 191472. This approval of buprenorphine for OBOT 
expands the availability of opioid agonist therapy beyond the scope of methadone and other 
specialized clinics, especially in rural settings. The use of buprenorphine medication counteracts 
the problematic, clinically significant impairment and distress often experienced by individuals 
who engage in illicit opioid use. Buprenorphine treatment prevents cravings, reduces the risks of 
HIV and Hepatitis C contraction, and allows for neurological brain structure stabilization and 
repair.  
The overt reliance on, and referral to, abstinence-focused community supports from 
medical and behavioral health personal is a glaring failure of the medical system to adapt and 
effectively meet the needs of individuals seeking recovery. Relapse is a natural part of recovery in 
chronic illness, and OUD is no exception. The binary stance of abstinence-based recovery sets an 
unobtainable ideal of perfection. Perpetuating this ideal within healthcare settings sets vulnerable 
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individuals with an OUD up for failure, stigmatization, and isolation, which further prevents them 
from seeking or accessing the resources they need. 
Due to the chronic nature of OUD and its similarities to other chronic illnesses, the medical 
community has an overwhelming responsibility to address it in a unique and comprehensive way. 
Despite the opioid epidemic and current public health emergency occurring within the United 
States, few articles addressing this issue resulted within this search. This lack of literature points 
to a major gap in research, educational activities, financial resource investment, and the continued 
lack of government intervention. In order to broaden understanding of OUD treatment among 
medical and public health professionals, future studies should focus on buprenorphine OBOT 
implementation in rural versus urban settings, community partnerships and collaboration, effects 
and benefits of established mentoring models, best practices for supportive counseling services, 
and the long-term impact of buprenorphine on patient’s health and quality of life. 
Significant barriers against OUD treatment, and buprenorphine OBOT in particular, still 
exist at institutional, educational, governmental, and provider levels. Stigma and miseducation 
surrounding individuals with OUD remain pervasive within the medical settings and the wider 
communities throughout the United States. Despite research showing that an abstinence-based 
approach is not effective on a population level, and that buprenorphine maintenance is beneficial 
front-line care, improving treatment retention and outcomes, addiction and recovery is still seen 
as a moral issue rather than a medical issue. This review focuses on buprenorphine OBOT 
specifically because of the overarching misconceptions surrounding opioid agonist treatment. The 
stigmatizing belief that individuals are simply “switching addictions” is a pervasive barrier for 
providers against offering inclusive, non-judgmental care.  
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At the end of 2017, there were 33,876 buprenorphine waivered physicians, making up 3.7% 
of the waiver eligible physicians within the United States87. Percentages of waivered nurse 
practitioners and physician assistance amongst the eligible pool were 1.7% and 0.8% 
respectively87. For those who have chosen to become waivered, a majority remain below their 
patient threshold90. This is interesting as one of the noted barriers was low patient interest or need 
for buprenorphine therapy. 
Low reimbursement rates for buprenorphine therapy is an additional concern. Providers 
are hesitant to take unfamiliar financial risks or make sacrifices for “difficult” individuals with 
OUD. Concerns about the stringent documentation requirements and staff capabilities seem to be 
closely tied to this barrier, as physicians report time lack of time, knowledge or interest as a 
barrier88. Remuneration rates vary by state and insurance providers, pointing to a need for federal 
policy regulation of an established billable rate for OUD treatment. 
Time constraints within office-based medical practices are another barrier noted by 
physicians. The additional documentation requirements required by the federal government for 
OBOT appear to be a closely related. Additionally, counseling requirements for OBOT patients, 
and the noted lack knowledge or familiarity with community counseling resources seems to further 
this barrier against implementation. These counseling requirements for OBOT patients, while 
federally mandated, are not tied to a specific treatment modality (e.g., group counseling). The 
nebulous nature of this requirement may be a deterrent for physicians looking for specific 
instruction as to the type of supportive services patients need. However, it may ultimately be a 
benefit as this freedom in clinical support services complements individualized treatment and 
person-centered models of care. Ultimately, physicians have the discretion to offer or refer the 
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supports they and their clients deem most appropriate and beneficial. Integrated models of care 
and greater collaboration between physicians and mental health professionals is necessary. 
Residency programs in the United States fail to educate and empower budding physicians 
with the tools needed to effectively address the opioid epidemic in a holistic and empathetic way, 
leaving individuals in need without office-based opioid treatment. Some doctors may even deny 
OUD symptomology within their patients. Few physicians in this review report receiving adequate 
OBOT training in their residency programs. Negative views of individuals who use illicit 
substances remain pervasive among medical residents and their preceptors. A lack of willingness 
or interest in engaging with persons with OUD remains strong among providers, and this is 
associated with a decision to stay un-waivered, regardless of available training, mentoring, or 
resources available for buprenorphine treatment implementation. Strict federal oversight and 
documentation for buprenorphine seem to only strengthen these existing barriers against obtaining 
a waiver, further decreasing a physician’s desire or perceived ability to treat individuals with OUD. 
Stories of physicians from within this literature review who have overcome the 
aforementioned barriers, as well as success stories of patients who received care within office-
based settings, are tremendous assets to challenging and deconstructing the structural and personal 
biases against the provision of buprenorphine in office-based settings. Within this review the 
importance of honesty, accountability, boundary setting, and having treatment contracts to 
complement OBOT and maintain its efficacy are apparent. Many physicians may find 
incorporating buprenorphine treatment within an established practice daunting since it deviates 
from routine practices and necessitates the physician and staff to adopt new roles. Doing so will 
require patience on both the clinician’s and clinical support staff’s part to incorporate OBOT and 
adopt  new roles. 
 50 
Mentorship for new or budding OBOT physicians is also crucial. No amount of formal 
training can force a physician to become non-judgmental, accepting and open to free and honest 
self-disclosure from a patient. However, mentorship from an established OBOT physician allows 
the necessary knowledge and experience surrounding inclusive buprenorphine treatment into their 
practice to be disseminated in a more personalized and intimate way. Physicians are able to develop 
skills, receive consultation and learn from other physicians in a less formal atmosphere. This is a 
level of support and guidance that is necessarily found in a personalized and informal way. The 
stories of these established physicians, their successes, failures and wider learnings, provide 
instrumental guidance to budding or newly waivered physicians looking to include this care. 
6.3 Limitations 
There are several limitations with this thesis. A literature search, review, and synthesis 
methodology were utilized. Limitations of this method are a reliance on outside literature, and the 
subsequent results of this thesis were further limited to one academic search engine. A more 
inclusive and expansive Boolean search process may increase the number of research studies that 
meet inclusion criteria. The research identified within this review is limited in number, 
demographic data, study designs, geographic scope, length of study time, use of secondary data, 
participant sample sizes, and has limited generalizability. However, they nonetheless assist in 
contextualizing a very difficult and nuanced subject, expand upon past research, and provide 
valuable guidance for medical and mental health professionals, as well as future research. 
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6.4 Implications and Recommendations 
Office-based buprenorphine treatment is an important part of the continuum of recovery 
and care88. Buprenorphine’s unique pharmacological properties as a partial mu receptor filler with 
a ceiling effect, and agonist qualities against illicit opioids, is well-fit for OBOT4,75,95. Successful 
implementation of buprenorphine OBOT has the potential to decrease mortality, limit the 
communication of disease, improve treatment outcomes and retention, and reduce overall 
healthcare costs77,95. Effective training and mentoring are necessary across all geographic regions 
throughout the United States, in order to instill physicians with the confidence needed to overcome 
the barriers documented within this review. 
Making changes to residency training about OUD is a critical element to ensuring inclusive 
educational curricula and implementation of buprenorphine OBOT. Focused symposiums within 
major hospital settings, open to patients, family members and medical personnel are one way of 
addressing the negative beliefs about persons with OUD. Working with state and national 
accreditation bodies to advocate for change in training duration and programmatic scope will 
reduce the barriers of stigma and increase physician wavering, thereby expanding OBOT 
provision.  
The federal government has made important strides towards increasing the availability of 
buprenorphine and OBOT by increasing the number of patients a waivered physician can assist 
with care, and their more recent approval of physician assistants and nurse practitioners to 
prescribe buprenorphine. However, these increases have done little to entice new and non-
prescribing physicians to receive a waiver, nor encourage currently waivered physicians to meet 
their patient limits. Physicians views of OUD and the effectiveness of MAT do not seem to have 
changed as a result of waver limit increases.  
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Policy makers should focus on increasing physician reimbursement rates. This literature 
review revealed concerns about financial viability for providers as a major barrier against 
buprenorphine OBOT. Rather than continuing to raise the waiver limits for physicians already 
prescribing, the federal government should look to increase remuneration as a way of enticing 
physicians not already practicing OBOT, thereby expanding the scope treatment availability. 
Increased rates for billing, coupled with expanded treatment and mentoring options, have the 
power to reduce multiple barriers simultaneously. This would also help ensure that providers who 
become waivered will continue to prescribe to waiver capacity without financial concern. 
Information regarding available resources for training and mentoring needs to be more 
widely circulated among physicians, such as through the Substance Abuse and Mental Health 
Services Administration’s Provider Clinical Support System96. According to their website, “PCSS 
provides evidence-based training and resources to give healthcare providers the skills and 
knowledge they need to treat patients with OUD.”97. This online platform connects trusted and 
established buprenorphine providers and addiction experts with newly waivered physicians, as 
well as individuals seeking support for successful buprenorphine implementation. It also offers 
webinars, group discussion and collaboration. Although free and easily accessed, this largely 
unadvertised resource remains underutilized and widely unknown among office-based physicians. 
Established and effective models of care for buprenorphine implementation and staff 
support need to be utilized, such as the Hub and Spoke Model pioneered in Vermont87. This model 
for networking and supporting treatment providers establishes a “hub” within an urban setting 
(e.g., hospital) that supports various outlying community resources, or “spokes.” Project ECHO 
out of New Mexico is another model that also holds promise. This digital platform links rural 
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primary health care physicians with urban hospital systems, offering practice support and 
individual case assistance98.  
More concerted efforts need to be made by public health professionals, policy makers, and 
community leaders, to research, evaluate and freely disseminate these effective models of care. 
Prioritizing buprenorphine treatment best practices will aid in reducing structural barriers and 
empower physicians in preventing and managing issues that may arise in the process of necessary 
office-based buprenorphine treatment implementation. 
Negative and marginalizing views of individuals with an OUD need to be addressed in 
inclusive and humanizing ways. This literature review demonstrates that some physicians continue 
to view patients as “difficult,” “high-maintenance,” “challenging,” and “stressful”86,88. Opioid Use 
Disorder is a chronic illness that remains largely viewed as a moral issue. Within this perception, 
persons suffering from OUD are frequently ignored or denied treatment because of something they 
“chose.” Long-term use of antidepressants to treat depression or anxiety is common within the 
medical field, yet the long-term use of opioid agonist medication to treat OUD is frequently viewed 
as inappropriate. This disconnect in treatment underscores the incongruency of how opioid based 
drugs are administered and individuals with OUD are treated in medical care settings. 
Language is an important tool in addressing stigma. Terms commonly used within the field 
of OUD treatment are loaded with connotations of laziness, weakness, poverty, or immorality. 
This review showed that individuals with OUD are still viewed and talked about in this way. 
Suggested change to language includes switching “addict” to “individual with a substance use 
disorder,” “sober” for “long-term recovery,” and “medication assisted treatment” for “medical 
treatment.” Seemingly simple changes to the language medical providers and public health 
professionals regularly use can have uncharacteristically positive results. 
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Powerful stories of experienced physicians who have overcome the personal and structural 
barriers against buprenorphine OBOT paint a potent and deeply humanizing picture of OUD 
treatment. Most notably, they describe the life-saving effects of buprenorphine within the lives of 
patients, their families and the wider community. Traditionally, the burden of sharing stories of 
success and long-term recovery has been on patients’ shoulders. However, providers have an equal 
duty to share their experiences of success and the fruits of treatment and recovery.  
Through a free and widespread sharing of such stories, a greater investment in education 
about OUD, increases in mentoring and other supportive resources, and an increase of 
reimbursement rates, we will begin to see a reduction in overdose deaths. Perhaps then more 
physicians will proudly proclaim that implementing buprenorphine treatment into their offices is 
“the most satisfying, personally nourishing medical activity I’ve done in my practice lifetime”87. 
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